IL303962A - The tricyclic compound - Google Patents

The tricyclic compound

Info

Publication number
IL303962A
IL303962A IL303962A IL30396223A IL303962A IL 303962 A IL303962 A IL 303962A IL 303962 A IL303962 A IL 303962A IL 30396223 A IL30396223 A IL 30396223A IL 303962 A IL303962 A IL 303962A
Authority
IL
Israel
Prior art keywords
group
substituted
compound
chloro
methoxyethyl
Prior art date
Application number
IL303962A
Other languages
English (en)
Hebrew (he)
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of IL303962A publication Critical patent/IL303962A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
IL303962A 2018-11-28 2019-11-27 The tricyclic compound IL303962A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018222530 2018-11-28
PCT/JP2019/046261 WO2020111087A1 (ja) 2018-11-28 2019-11-27 複素環化合物

Publications (1)

Publication Number Publication Date
IL303962A true IL303962A (en) 2023-08-01

Family

ID=70853784

Family Applications (2)

Application Number Title Priority Date Filing Date
IL283368A IL283368B2 (en) 2018-11-28 2019-11-27 Imidazo[2,1-b]pyridazin-7-yl urea compound and medicament containing the compound
IL303962A IL303962A (en) 2018-11-28 2019-11-27 The tricyclic compound

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL283368A IL283368B2 (en) 2018-11-28 2019-11-27 Imidazo[2,1-b]pyridazin-7-yl urea compound and medicament containing the compound

Country Status (16)

Country Link
US (4) US12152027B2 (cg-RX-API-DMAC7.html)
EP (1) EP3888652A4 (cg-RX-API-DMAC7.html)
JP (2) JP6972384B2 (cg-RX-API-DMAC7.html)
KR (2) KR102646470B1 (cg-RX-API-DMAC7.html)
CN (2) CN113038948B (cg-RX-API-DMAC7.html)
AU (1) AU2019390863B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021009994A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120774A1 (cg-RX-API-DMAC7.html)
IL (2) IL283368B2 (cg-RX-API-DMAC7.html)
MX (2) MX2021005877A (cg-RX-API-DMAC7.html)
MY (1) MY209902A (cg-RX-API-DMAC7.html)
PH (1) PH12021551251A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105652XA (cg-RX-API-DMAC7.html)
TW (3) TW202438498A (cg-RX-API-DMAC7.html)
WO (1) WO2020111087A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202104402B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021005877A (es) * 2018-11-28 2021-07-16 Takeda Pharmaceuticals Co Compuesto heterociclico.
WO2021241611A1 (ja) 2020-05-27 2021-12-02 武田薬品工業株式会社 複素環化合物の製造方法
AU2021361057A1 (en) * 2020-10-16 2023-06-08 Rarefied Biosciences, Inc. Malt1 modulators and uses thereof
GB202018412D0 (en) 2020-11-23 2021-01-06 Exscientia Ltd Malt-1 modulators ii
EP4458819A4 (en) 2021-12-30 2026-01-07 Shanghai Hansoh Biomedical Co Ltd TRICYCLIC DERIVATIVE INHIBITOR, ITS PREPARATION PROCESS AND ITS USE
WO2023149450A1 (ja) 2022-02-02 2023-08-10 小野薬品工業株式会社 Malt1阻害薬を有効成分として含むがん治療剤
US20250188081A1 (en) * 2023-12-08 2025-06-12 Shaman Pharma, LLC Method for Production of Spiro-Oxindole and Indoxyl Derivatives of Mitragynine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2288521A1 (fr) 1974-10-25 1976-05-21 Merck Patent Gmbh Nouvelles penicillines et procede pour leur preparation
CN1065243C (zh) * 1995-05-31 2001-05-02 住友制药株式会社 新的二氮杂萘衍生物
GB9720052D0 (en) 1997-09-19 1997-11-19 Smithkline Beecham Plc Novel compounds
GB201321734D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
CN106170489B (zh) 2014-05-28 2019-05-03 诺华股份有限公司 新的吡唑并嘧啶衍生物及其作为malt1抑制剂的用途
CN108473499B (zh) 2015-11-13 2021-07-23 诺华股份有限公司 新颖的吡唑并嘧啶衍生物
WO2018020474A1 (en) 2016-07-29 2018-02-01 Lupin Limited Substituted thiazolo-pyridine compounds as malt1 inhibitors
WO2018085247A1 (en) 2016-11-01 2018-05-11 Cornell University Compounds for malt1 degradation
JP7142022B2 (ja) * 2017-03-08 2022-09-26 コーネル・ユニバーシティー Malt1の阻害剤およびそれらの使用
US20200111087A1 (en) * 2018-10-08 2020-04-09 Jinlei Zhou Method for encrypting digital contract document between contractors
MX2021005877A (es) 2018-11-28 2021-07-16 Takeda Pharmaceuticals Co Compuesto heterociclico.

Also Published As

Publication number Publication date
KR102646470B1 (ko) 2024-03-11
US11230545B2 (en) 2022-01-25
MY209902A (en) 2025-08-09
MX2024003064A (es) 2024-03-27
MX2021005877A (es) 2021-07-16
CN113038948A (zh) 2021-06-25
US12152027B2 (en) 2024-11-26
AU2019390863A1 (en) 2021-06-24
KR102359143B1 (ko) 2022-02-08
TW202306956A (zh) 2023-02-16
JP6972384B2 (ja) 2021-11-24
US20220089595A1 (en) 2022-03-24
NZ777412A (en) 2024-05-31
IL283368B1 (en) 2024-09-01
PH12021551251A1 (en) 2021-12-06
CN113038948B (zh) 2024-07-12
TWI784213B (zh) 2022-11-21
IL283368B2 (en) 2025-01-01
TW202039484A (zh) 2020-11-01
US11897879B2 (en) 2024-02-13
AU2019390863A2 (en) 2021-07-01
CA3120774A1 (en) 2020-06-04
TW202438498A (zh) 2024-10-01
JPWO2020111087A1 (ja) 2021-09-27
WO2020111087A1 (ja) 2020-06-04
US20220048916A1 (en) 2022-02-17
US20250034141A1 (en) 2025-01-30
US20210332045A1 (en) 2021-10-28
WO2020111087A9 (ja) 2021-01-21
AU2019390863B2 (en) 2025-02-20
KR20220019848A (ko) 2022-02-17
BR112021009994A2 (pt) 2021-08-17
JP7434249B2 (ja) 2024-02-20
EP3888652A1 (en) 2021-10-06
TWI848400B (zh) 2024-07-11
SG11202105652XA (en) 2021-06-29
EP3888652A4 (en) 2022-10-19
JP2022017461A (ja) 2022-01-25
IL283368A (en) 2021-07-29
CN118420620A (zh) 2024-08-02
ZA202104402B (en) 2023-01-25
KR20210092301A (ko) 2021-07-23

Similar Documents

Publication Publication Date Title
IL303962A (en) The tricyclic compound
CN107108637B (zh) 三唑并嘧啶化合物及其用途
US9617267B2 (en) Compounds and methods for kinase modulation, and indications therefor
US9000186B2 (en) Ring-fused heterocyclic derivative
IL315586A (en) Substituted tricyclic compounds as parp inhibitors and the use thereof
US20240109881A1 (en) Heteroaryl Compounds as Ligand Directed Degraders of IRAK4
IL267299B (en) Cdk4/6 inhibitor
US10519110B2 (en) Heterocyclic compound
CN108069938A (zh) 2,4-二取代吡啶类化合物及其制备方法和应用
RU2808435C2 (ru) Гетероциклическое соединение
HK40051951A (zh) 杂环化合物
HK40051951B (zh) 杂环化合物
WO2013100018A1 (ja) 複素環化合物
JP2005035935A (ja) オキサゾール化合物およびその用途
HK1249502B (zh) 吡啶并[3,4-d]嘧啶衍生物及其药学上可允许的盐